ストックスクリーナーアプリを入手
0.9894
6.95%
0.0643
プレマーケット:
1.00
0.0106
+1.07%
前日終値:
$0.9251
開ける：
$0.93
24時間の取引高:
1.15M
Relative Volume:
0.55
時価総額：
$112.16M
収益：
-
当期純損益:
$-225.14M
株価収益率:
-0.5048
EPS:
-1.96
ネットキャッシュフロー:
$-192.27M
1週間 パフォーマンス:
+5.82%
1か月 パフォーマンス:
+87.17%
6か月 パフォーマンス:
+69.80%
1年 パフォーマンス:
-43.46%
1日の値動き範囲:
$0.9251
$1.00
1週間の範囲:
$0.84
$1.06
52週間の値動き範囲:
$0.3546
$2.74
Invivyd Inc Stock (IVVD) Company Profile
IVVD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
0.9894 | 112.16M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-05 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-03-26 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | 開始されました | H.C. Wainwright | Buy |
Invivyd Inc (IVVD) 最新ニュース
H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall - Insider Monkey
Invivyd stock target cut to $5 by H.C. Wainwright, retains Buy rating - Investing.com Nigeria
Invivyd (NASDAQ:IVVD) Price Target Lowered to $5.00 at HC Wainwright - Defense World
Invivyd (IVVD) Analyst Rating Update: Price Target Lowered | IVV - GuruFocus
Invivyd (IVVD) Price Target Reduced by H.C. Wainwright Amid Reve - GuruFocus
Invivyd (IVVD) Price Target Reduced by H.C. Wainwright Amid Revenue Concerns | IVVD Stock News - GuruFocus
Invivyd (IVVD) Publishes Strong Phase 3 Trial Results for COVID-19 Antibody | IVVD Stock News - GuruFocus
Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive S - The Manila Times
Breakthrough COVID-19 Drug PEMGARDA Achieves 84% Protection in First Modern U.S. Phase 3 Trial - Stock Titan
Invivyd’s antibody gains spot in cancer guidelines for COVID-19 PrEP By Investing.com - Investing.com South Africa
Invivyd’s antibody gains spot in cancer guidelines for COVID-19 PrEP - Investing.com Australia
Invivyd's Pemgarda Added to NCCN Guidelines in Oncology for B-Cell Lymphomas - marketscreener.com
Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas - The Manila Times
Invivyd (IVVD) Monoclonal Antibody Added to NCCN Guidelines for B-Cell Lymphomas | IVVD Stock News - GuruFocus
NCCN Guidelines Now Include PEMGARDA for B-Cell Lymphoma COVID Protection | IVVD Stock News - Stock Titan
Invivyd (IVVD) Applauds FDA's Steps to Address COVID-19 Booster Uncertainty | IVVD Stock News - GuruFocus
Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19 - The Manila Times
Invivyd Commends FDA on New Framework for COVID-19 Vaccines Amidst Uncertainty Regarding Booster Efficacy - Nasdaq
FDA Questions COVID Booster Benefits While Invivyd's Antibody Shows 84% Protection in Modern Trials - Stock Titan
Invivyd at H.C. Wainwright Conference: Strategic Moves in Antibodies By Investing.com - Investing.com Nigeria
Invivyd Holds Annual Stockholders Meeting, Elects Directors - TipRanks
Invivyd at H.C. Wainwright Conference: Strategic Moves in Antibodies - Investing.com
Upstream Bio Strengthens Leadership Team: Former Invivyd Executive Takes CTO Role for Critical Clinical Program - Stock Titan
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates - MSN
Invivyd (IVVD) Maintains Buy Rating with Stable Price Target | I - GuruFocus
Invivyd, Inc. (NASDAQ:IVVD) Q1 2025 Earnings Call Transcript - Insider Monkey
Invivyd Q1 2025 slides: Revenue grows amid regulatory hurdles and cash concerns - Investing.com Nigeria
Earnings call transcript: Invivyd Q1 2025 sees stock drop amid earnings miss - Investing.com Canada
Earnings call transcript: Invivyd Q1 2025 sees stock drop amid earnings miss By Investing.com - Investing.com South Africa
Invivyd Reports Q1 2025 Financial Results and Outlook - TipRanks
Invivyd’s Earnings Call: Strategic Moves Amid Challenges - TipRanks
Why JD.com Stock Slumped on Thursday - The Globe and Mail
INVIVYD SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc.IVVD, A - Barchart.com
Transcript : Invivyd, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
Invivyd (IVVD) Reports Q1 Revenue Below Expectations Amid Strate - GuruFocus
Invivyd (IVVD) Reports Q1 Revenue Below Expectations Amid Strategic Shift | IVVD Stock News - GuruFocus
Invivyd Reports Q1 2025 Financial Results and Highlights - TipRanks
INVIVYD Earnings Results: $IVVD Reports Quarterly Earnings - Nasdaq
Invivyd, Inc. SEC 10-Q Report - TradingView
Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Invivyd, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Invivyd calls for modernized FDA vaccine guidelines By Investing.com - Investing.com Canada
Invivyd Launches New Measles Antibody Discovery Program: Retail Traders Bet On ‘Future Of Medicine’ - MSN
What To Expect From Invivyd Inc (IVVD) Q1 2025 Earnings - Yahoo Finance
Invivyd (IVVD) Urges FDA to Revise COVID-19 Vaccine Development - GuruFocus
Invivyd Inc (IVVD) 財務データ
収益
当期純利益
現金流量
EPS
Invivyd Inc (IVVD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MCGUIRE TERRANCE | Director |
Dec 27 '24 |
Sale |
0.52 |
83,744 |
43,647 |
3,256,776 |
| MCGUIRE TERRANCE | Director |
Dec 30 '24 |
Sale |
0.48 |
86,545 |
41,784 |
3,170,231 |
| MCGUIRE TERRANCE | Director |
Dec 20 '24 |
Sale |
0.42 |
119,805 |
50,725 |
3,568,274 |
| MCGUIRE TERRANCE | Director |
Dec 26 '24 |
Sale |
0.54 |
83,817 |
45,563 |
3,340,520 |
| MCGUIRE TERRANCE | Director |
Dec 24 '24 |
Sale |
0.51 |
68,161 |
34,503 |
3,424,337 |
| MCGUIRE TERRANCE | Director |
Dec 23 '24 |
Sale |
0.45 |
75,776 |
34,076 |
3,492,498 |
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):